Mirum Pharmaceuticals, Inc. MIRM
91.95 USD 0.00 (+0.00%)
Regular-session close
91.60 -0.35 -0.38%
Pre-market · Nov 18, 7:58 AM ET
89.27 Day range 92.31
63.23 52-week range 130.00
- YTD
- +16.41%
- 1 year
- +27.34%
News
seekingalpha.com AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most…
businesswire.com Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).benzinga.com Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $194 Citigroup analyst Yigal Nochomovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $184 to $194.
zacks.com MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.benzinga.com Leerink Partners Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $140 Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $154 to $140.
benzinga.com CORRECTION: RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Lisa Walter reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com RBC Capital Reiterates Outperform on Mirum Pharmaceuticals, Maintains $155 Price Target RBC Capital analyst Luca Issi reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and maintains $155 price target.
benzinga.com Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Raises Price Target to $167 Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and raises the price target from $144 to $167.
benzinga.com HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $202 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $200 to $202.
benzinga.com Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $160 Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $155 to $160.
benzinga.com Mirum Pharmaceuticals Q3 2026 Earnings Call Transcript Mirum Pharmaceuticals (NASDAQ:MIRM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $680.000M-$700.000M to $715.000M-$720.000M vs $698.093M Est Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $680.000 million-$700.000 million to $715.000 million-$720.000 million vs $698.093 million estimate.
benzinga.com Mirum Pharmaceuticals Q3 EPS $(0.87) Misses $(0.51) Estimate, Sales $185.721M Beat $178.078M Estimate Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.51) by 70.59 percent. This is a 1840 percent decrease over…
benzinga.com Mirum Pharmaceuticals Announces Results From Cohort 2 Of Pivotal PROGRESS Study Of ATEBRIOZ - Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to…
benzinga.com TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145 TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.
